Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

Aug. 23, 2024 — A collaborative investigation among experts in Alzheimer's disease and multiple sclerosis (MS) finds evidence that MS patients are less likely to have amyloid plaques ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

These data and 12 additional abstracts will be presented at the 40 th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark taking place ...

Although there is currently no cure for multiple sclerosis (MS), current treatments focus on limiting further damage, easing symptoms, and avoiding complications. If you have a type of multiple ...